Discovery and structural-activity relationship of N-benzyl-2-fluorobenzamides as EGFR/HDAC3 dual-target inhibitors for the treatment of triple-negative breast cancer. - Ge GH; Guo S; Li TT; Wang YP; Liu LR; Yu WH; Hu H; Zheng YM; Yan JH; Sun YH; Liang JW; Meng FH; et al. (Bioorganic & medicinal chemistry letters, 2025)